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Abstract
The aim of this study was to determine whether left atrial ejection fraction (LAEF) quantified with cardiovascular magnetic 
resonance (CMR) was different between heart failure with preserved ejection fraction (HFpEF) and controls, and its relation 
to prognosis. As part of our single-centre, prospective, observational study, 188 subjects (HFpEF n = 140, controls n = 48) 
underwent phenotyping with contrast-enhanced CMR, transthoracic echocardiography, blood sampling and six-minute walk 
testing. LAEF was calculated using the biplane method. Atrial fibrillation (AF) was present in 43 (31%) of HFpEF subjects. 
Overall, LAEF (%) was lower in HFpEF patients inclusive of AF (32 ± 16) or those in sinus rhythm alone (41 ± 12) com-
pared to controls (51 ± 11), p < 0.0001. LAEF correlated inversely with maximal and minimal left atrial volumes indexed 
(r =  − 0.602, r =  − 0.762), and plasma N-terminal pro-atrial natriuretic peptide (r =  − 0.367); p < 0.0001. During median 
follow-up (1429 days), there were 67 composite events of all-cause death or hospitalization for heart failure (22 deaths, 45 
HF hospitalizations) in HFpEF. Lower LAEF (below median) was associated with an increased risk of composite endpoints 
(Log-Rank: all p = 0.028; sinus p = 0.036). In multivariable Cox regression analysis, LAEF (adjusted hazard ratio [HR] 
0.767, 95% confidence interval [CI] 0.591–0.996; p = 0.047) and indexed extracellular volume (HR 1.422, CI 1.015–1.992; 
p = 0.041) were the only parameters that remained significant when added to a base prognostic model comprising age, prior 
HF hospitalization, diastolic blood pressure, lung disease, NYHA, six-minute-walk-test-distance, haemoglobin, creatinine 
and B-type natriuretic peptide. CMR-derived LAEF is lower in HFpEF compared to healthy controls and is a strong prog-
nostic biomarker.
Keywords Cardiovascular magnetic resonance imaging · Heart failure with preserved ejection fraction · Prognosis · Left 
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Introduction
Left atrial (LA) remodeling and dysfunction have been 
implicated in the pathophysiology of heart failure (HF) 
and are associated with poorer outcomes across a range of 
pathologies [1]. To date, the evidence base for such observa-
tions has largely been derived from echocardiography which 
is reliant upon adequate LA endocardial border definition for 
both volumetric and strain assessments [2]. Cardiovascular 
magnetic resonance imaging (CMR) affords superior spatial 
resolution, excellent contrast between blood pool and myo-
cardium, has excellent reproducibility and is the current gold 
standard for LA volumetric [3] and functional assessment in 
sinus rhythm [4] or atrial fibrillation (AF) [5].
Heart failure with preserved ejection fraction (HFpEF) 
currently accounts for a significant proportion of all HF 
patients. Unlike heart failure with reduced ejection fraction 
(HFrEF), HFpEF still remains poorly understood and lacks 
proven, effective therapies [6]. Currently, prospective CMR 
studies assessing LA dysfunction in HFpEF are lacking. In 
this prospective, observational study of a well-characterized 
cohort with HFpEF, we assessed whether CMR-derived left 
atrial ejection fraction (LAEF) is different compared to con-
trols and is of prognostic value.
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One hundred and fifty five patients with HFpEF were 
recruited in an observational, cohort study conducted at a 
single tertiary cardiac centre. HFpEF inclusion criteria were 
clinical or radiographic evidence of HF, left ventricular ejec-
tion fraction (LVEF) > 50% on transthoracic echocardiogra-
phy (TTE) and age ≥ 18 years. The exclusion criteria were 
as previously described [7].
For comparison with HFpEF, 48 asymptomatic controls 
(age- and sex-matched) were recruited. Hypertensive sub-
jects were included in this group (n = 22) since hyperten-
sion is highly prevalent in this age group of patients. The 
study was approved by the National Research Ethics Ser-
vice (reference: 12/EM/0222). Written informed consent was 
obtained from all subjects prior to participation.
All subjects underwent comprehensive clinical assess-
ment and blood sampling, TTE and CMR during the same 
visit. A standardized six minute walk test (6MWT) was used 
to quantify exercise capacity [8].
Blood sampling
Blood was sampled for B-type natriuretic peptide ([BNP]-
immunoassay, Siemens, Erlangen, Germany), haematocrit, 
haemoglobin and renal function (urea, creatinine). Plasma 
samples were analysed in a single batch for N-terminal pro-
atrial natriuretic peptide (NT-proANP), a marker of atrial 
stress/stretch, using a Luminex® bead-based multiplex assay 
as previously described [9].
Transthoracic echocardiography
Echocardiography was performed by accredited sonogra-
phers in accordance with American Society of Echocardi-
ography guidelines using an iE33 system (Philips Medical 
Systems, Best, The Netherlands) as previously reported [7, 
10]. LVEF was calculated using the biplane method or esti-
mated visually where endocardial border definition was sub-
optimal. Septal and lateral mitral annular diastolic velocities 
were averaged and used to derive E/E′ as an overall measure 
of diastolic function.
CMR protocol
All CMR scans were performed on a 3-Tesla scanner (Sie-
mens Skyra, Erlangen, Germany) with an 18-channel cardiac 
coil as previously detailed [7, 10]. Retrospective ECG gat-
ing was nominally used for image acquisition. In cases of 
arrhythmia, prospective gating was employed. In brief, the 
protocol comprised: standard long- and short-axis cine imag-
ing; basal, mid-ventricular and apical short-axis T1 mapping 
pre- and post-contrast and late gadolinium enhancement 
(LGE) imaging at least 10 min after the final injection of 
contrast (Gadovist, Bayer Healthcare, Germany-total dose 
0.15 mmol/kg). All cine images were acquired using bal-
anced steady state free precession (SSFP) sequences and 
the following parameters: slice thickness 8 mm; distance 
factor 25%; image matrix 256 × 204 and segments amended 
according to heart rate ( < 70 b.p.m = 15 segments; 70–80 
b.p.m = 12 segments; 80–100 b.p.m = 11 segments).
CMR analysis
All images were analysed by a single operator (PK) blinded 
to clinical data, using CVI42 software (Circle Cardiovascu-
lar Imaging, Calgary, Canada). Left ventricular volumes, 
EF and mass were calculated from the short-axis cine stack 
excluding papillary muscles and trabeculations [7]. Qualita-
tive assessment of LGE images was undertaken by consen-
sus of 2 experienced observers (PK, ASHC) and in cases of 
disagreement a third (GPM) for identifying the presence and 
pattern of focal fibrosis i.e. MI or non-MI fibrosis. Measures 
of diffuse myocardial fibrosis, namely ECV (extracellular 
volume) and iECV (ECV indexed to body surface area) 
were also calculated from mid-ventricular T1 mapping, as 
described by our group with excellent reproducibility [10]. 
Segments with MI or artefact were excluded from final T1 
and ECV calculation, and segmental values were then aver-
aged. Regions of focal non-MI fibrosis were included in our 
ECV (and iECV) calculations.
The biplane area-length method (excluding the append-
age and pulmonary veins—Fig. 1) was employed for LA 
volumetric [11] and functional analysis [12]. The LA endo-
cardial border was manually contoured in both the 2- and 
4-chamber views with the mitral annulus serving as the divi-
sion between the LA and LV. The maximum LA area was 
contoured in the frame immediately prior to mitral valve 
opening. The minimum LA area was contoured in the frame 
immediately after mitral valve closure. LA volumes (LAV) 
were calculated using the area-length method, where: vol-
ume = (0.85 × area2)/length. LAEF was derived as follows: 
LAEF = (LAVmax − LAVmin) /LAVmax. Surrogates of 
LA reservoir function i.e. reservoir volume ([LAVmax 
− LAVmin]) and LA conduit function i.e. conduit volume 
([LV stroke volume − LA reservoir volume]) were also cal-
culated. LAVImax > 40 ml/m2 was used to define LA dila-
tion [11]. All volumetric and mass data were indexed to 
body surface area.
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Follow‑up and endpoints
The primary endpoint was the composite of all-cause mor-
tality or first HF hospitalization. Hospital databases and 
patient records were sourced to obtain outcome data. Patient 
follow-up was for a minimum of 12 months post-study entry. 
Only the first event was included in the outcome analysis.
Statistical analysis
Statistical tests were performed using SPSS v22. Normality 
for continuous data was assessed using histograms, Q–Q 
plots and the Shapiro–Wilk test. Summary data are pre-
sented as mean (± standard deviation) or median (25–75% 
interquartile range). Between group differences were com-
pared using the unpaired t-test, Mann–Whitney U test and 
the Chi-square test as appropriate. BNP and creatinine were 
 log10 transformed before analysis. Pearson’s and Spearman’s 
correlations were performed to check for potential associa-
tions of LAEF with other continuous variables. Assessments 
of intra-observer and inter-observer variability for LA func-
tion were undertaken on ten randomly selected patients, 
a minimum of 4 weeks apart (by PK and JRA). Receiver 
operator characteristics (ROC) analyses were undertaken 
to assess the strength of the discriminatory capabilities of 
LAEF in distinguishing HFpEF from controls.
Kaplan–Meier analysis was undertaken to calculate 
event rates. Differences in survival curves were tested using 
the Log-Rank test. Cox proportional hazards analysis was 
undertaken to identify baseline variables associated with the 
composite endpoint. A base multivariable prognostic clinical 
model was created comprising clinical parameters shown to 
have historically strong prognostic importance in HF and 
univariable associations with the endpoint of p < 0.10. All 
remaining covariates associated with the endpoint at p < 0.10 
were then entered into subsequent multivariable analysis to 
identify independent predictors using stepwise elimina-
tion methods. Continuous variables were Z-standardized to 
enable comparison of hazard ratios (HR) based upon one 
standard deviation increase in the predictor variable. The 
incremental prognostic benefit of LAEF beyond the base 
model was also assessed by comparing the area under the 
curves (AUCs) from ROC analysis.
Results
HFpEF versus controls
Following CMR, 15 HFpEF patients were diagnosed [7] 
with either hypertrophic cardiomyopathy (n = 10) or con-
strictive pericarditis (n = 5) and excluded from further 
analysis. Our final cohort thus comprised a total of 188 
participants (Fig. 2). Baseline demographics and imaging 
characteristics are summarized in Tables 1 and 2.
HFpEF and healthy controls were well matched for age 
(73 years) and sex. Approximately two-thirds of HFpEF 
patients had experienced prior hospital admissions for 
decompensated HF or had radiographic evidence of pul-
monary congestion. Consistent with prior studies, HFpEF 
was frequently associated with co-morbidities including 
obesity, diabetes, hypertension and atrial fibrillation (AF). 
HFpEF patients had worse renal function and lower haemo-
globin. A significant minority of HFpEF also had known 
ischaemic heart disease (22%, MI noted in 16%) and lung 
disease (17%). Furthermore, HFpEF patients had dramati-
cally poorer exercise capacity (shorter 6MWT distance) 
and nearly one-third were in New York Heart Association 
(NYHA) III/IV.
Imaging data
Indices of diastolic dysfunction as per European Society of 
Cardiology (ESC) guidelines i.e. BNP, E/E′, LAVImax, LV 
mass were significantly higher in HFpEF (Tables 1, 2). Com-
pared to controls, the HFpEF group had greater concentric 
remodeling with increased LV mass/volume and a higher 
burden of both focal (MI and non-MI) and diffuse fibrosis 
(ECV, iECV); p < 0.0001 for all.
Fig. 1  Calculation of left atrial ejection fraction. Cine 2- and 4-cham-
ber images illustrating contoured maximum (a) and minimum (b) left 
atrial areas for volume (and ejection fraction) derivation
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Fig. 2  Study recruitment overview. Flow chart illustrating recruitment and CMR assessments. CMR cardiovascular magnetic resonance imaging, 
HFpEF heart failure with preserved ejection fraction
Table 1  Baseline clinical 
characteristics
Values are mean ± SD, n (%) or median, interquartile range. The p values are for the t-test or chi-square test
BNP B-type natriuretic peptide, COPD chronic obstructive pulmonary disease, HF heart failure, HFpEF 
heart failure with preserved ejection fraction, IQR interquartile range, NA not applicable, NTpro-ANP 








 Age (years) 73 ± 9 73 ± 5 0.820
 Male (%) 68 (49) 24 (50) 0.977
Clinical
 Heart rate (beats/min) 70 ± 14 68 ± 10 0.308
 Systolic blood pressure (mmHg) 145 ± 25 151 ± 24 0.001
 Diastolic blood pressure  (mmHg) 74 ± 12 79 ± 10 0.006
 Body mass index (kg/m2) 34 ± 7 25 ± 3  < 0.0001
 Atrial fibrillation (%) 43 (31) 0 (0)  < 0.0001
 Prior HF hospitalization (%) 92 (66) NA –
 Diabetes (%) 75 (54) 0 (0)  < 0.0001
 Hypertension (%) 127 (91) 22 (46)  < 0.0001
 Angina (%) 23 (16) 0 (0) 0.003
 Known myocardial infarction (%) 16 (11) 0 (0)  < 0.0001
 Asthma or COPD (%) 24 (17) 3 (6) 0.134
Functional status
 NYHA III/IV (%) 43 (31) NA 0.551
 6MWT distance (m) 180 (120–250) 380 (350–440)  < 0.0001
Laboratory indices
 Urea (mmol/L) 9 ± 4 6 ± 1  < 0.0001
 Creatinine (mmol/L) 89 (73–115) 71 (56–85)  < 0.0001
 Haemoglobin (g/L) 129 ± 22 140 ± 15 0.003
 BNP (ng/L) 136 (66–254) 33 (24–44)  < 0.0001
 NTpro-ANP (pg/ml) 6443 (4362–8511) 4019 (3362–4475)  < 0.0001
The International Journal of Cardiovascular Imaging 
1 3
LA parameters
HFpEF subjects had higher plasma NT-proANP levels, 
larger atria and lower LAEF (32 ± 16) compared to controls: 
overall (51 ± 11), with hypertension (49 ± 12) and without 
hypertension (52 ± 11); p < 0.0001 for all (also see Table 2). 
There was no significant difference in LAEF between hyper-
tensive and non-hypertensive controls (p = 0.324). Within 
HFpEF (Supplementary Table 1), AF was present in 31% 
and was associated with significantly higher LA volumes 
and lower LAEF (LAVImax 76 mls, LAVImin 66mls, 
LAEF 14%) compared to sinus rhythm (LAVImax 43mls, 
LAVImin 26mls, LAEF 41%, p < 0.0001). In HFpEF, normal 
LA size was noted in: 36% overall, 5% in AF and 50% in 
sinus rhythm. LAEF was lower in the presence of dilated LA 
compared to non-dilated LA: overall 26 ± 14 versus 44 ± 13; 
AF 13 ±  versus 36 ± 17; sinus rhythm 37 ± 9 versus 45 ± 13, 
p < 0.0001 for all.
In the whole cohort, a LAEF threshold value below 44% 
best discriminated HFpEF from controls using maximal sen-
sitivity–specificity analysis; ROC-AUC 0.794, p < 0.00001. 
In sub-group analysis of sinus rhythm subjects, the same 
LAEF threshold yielded a ROC-AUC of 0.727, p < 0.00001.
LAEF correlations
LAEF correlated inversely with echocardiographic E/E′ 
(Pearson’s r =  − 0.247, p = 0.001). There were further 
moderate to strong inverse correlations between LAEF, 
NTproANP (Spearman’s r =  − 0.367) and LA volumes 
(LAVImax Pearson’s r =  − 0.602, LAVImin r =  − 0.762, 
see Fig. 3); p < 0.0001 for all. As LAEF diminished, LA 
Table 2  Baseline imaging 
characteristics
ECV extracellular volume, iECV indexed to body surface area, extracellular volume LA left atrium, LAEF 
left atrial ejection fraction, LAVImax left atrial maximal volume indexed to body surface area, LAVImin left 
atrial minimal volume indexed to body surface area, LV left ventricle, LVEDVI left ventricular end-diastolic 
volume indexed to body surface area, LVEF left ventricular ejection fraction, LVESVI left ventricular end-







 Pulmonary oedema (%) 97 (69) NA –
 Raised cardiothoracic ratio (%) 101 (72) NA –
 Pleural effusion (%) 49 (35) NA –
Echocardiography
 E/E′ 13 ± 6 9 ± 3  < 0.0001
CMR LV parameters
 LVEF (%) 56 ± 5 58 ± 5 0.019
 LVEDVI (ml/m2) 79 ± 18 81 ± 14 0.409
 LVESVI (ml/m2) 35 ± 10 34 ± 8 0.541
 LV mass indexed (g/m2) 52 ± 15 46 ± 9  < 0.0001
 LV mass/LVEDV 0.68 ± 0.16 0.57 ± 0.09  < 0.0001
 Presence of MI (%) 23 (16) 0 (0)  < 0.0001
 MI size (% of LV mass) 3.0 (1.3–4.6) 0 (0)  < 0.0001
 Presence of non-MI focal fibrosis   (%) 49 (35) 5 (10)  < 0.0001
 Non-MI fibrosis size (% of LV mass) 2.9 (1.4–6.5) 2.4 (0.6–3.6) 0.002
 Native myocardial T1 (ms) 1234 ± 73 1197 ± 91 0.021
 Post-contrast myocardial T1 (ms) 461 ± 63 495 ± 85 0.011
 ECV (%) 28 ± 4.6 25 ± 3.2  < 0.0001
 iECV (ml/m2) 13.7 ± 4 10.9 ± 2.8  < 0.0001
CMR LA parameters
Overall: all subjects including atrial fibrillation
 LAEF (%) 32 ± 16 51 ± 11  < 0.0001
 Normal-sized LA (%) 50 (36) 33 (69)  < 0.0001
 LAVImax (ml/m2) 53 ± 25 35 ± 12  < 0.0001
 LAVImin (ml/m2) 38 ± 26 17 ± 8  < 0.0001
 LA reservoir volume indexed ( ml/m2) 15 ± 7 17 ± 6 0.025
 LA conduit volume indexed (ml/m2) 29 ± 9 30 ± 9  < 0.677
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volumes increased. Linear fit models of LAEF against the 
inverse of LAVImax  (r2 = 0.253, p < 0.0001) and LAVImin 
 (r2 = 0.485, p < 0.0001) are illustrated in Fig. 3. iECV did 
not correlate with LAEF (Pearson’s r =  − 0.067; p = 0.527).
Inter‑observer and intra‑observer assessments
Inter-observer and intra-observer variability agreements for 
LA volumes and LAEF were excellent (intra-class correla-
tion coefficients 0.95–0.99; Supplementary Table 2).
Survival analysis
During median follow-up of 1429 days (1157–1657), there 
were a total of 67 composite events (48%, 22 deaths, 45 HF 
hospitalizations) in patients with HFpEF. The event rate was 
higher in the AF sub-group than in sinus rhythm (55.8% vs 
44.3%, p = 0.210). There were no events in the control group. 
No subjects were lost to follow-up.
Cox regression analysis
On univariable analysis comprising all HFpEF subjects, 
18 parameters were associated with adverse outcomes 
(Table 3). AF was not significantly associated with out-
comes on univariable analysis (p = 0.221). Plasma urea and 
creatinine exhibited collinearity. Of the urivariable predic-
tors, nine variables (age, prior HF hospitalization, diastolic 
blood pressure, lung disease, NYHA class, 6MWT distance, 
haemoglobin, creatinine and BNP) were entered into a base 
clinical model. Of the remaining variables with univariate 
endpoint association of p < 0.10, LAEF (adjusted hazard 
ratio [HR] 0.767, 95% confidence interval [CI] 0.591–0.996; 
p = 0.047) and iECV (HR 1.422, CI 1.015–1.992; p = 0.041) 
were the only parameters to retain statistical significance on 
multivariable analysis in addition to the base model.
Fig. 3  Associations of left atrial ejection fraction with left atrial vol-
umes. Scatter plot illustrating the relationship between left atrial ejec-
tion fraction (LAEF) and the inverse of: maximum left atrium vol-
ume indexed-LAVImax (left panel) or minimum left atrium volume 
indexed-LAVImin (right panel)
Table 3  Univariable predictors for the composite endpoint of death 
and/or hospitalization with heart failure
Abbreviations are as for Tables 1 and 2; Hazard ratios are based upon 
one standard deviation increase in the predictor variable for continu-
ous variables which are Z-standardized
CI confidence interval
a Parameters entered into the base clinical multivariable model
Hazard ratio (95% CI) P value
Univariable predictors of outcome
 Clinical
  Agea 1.386 (1.084–1.772) 0.009
  Average  DBPa 0.650 (0.492–0.858) 0.002
  Prior HF  hospitalizationa 2.902 (1.553–5.423) 0.001
  Lung  diseasea 1.891 (1.077–3.321) 0.027
  NYHA III/IVa 1.703 (1.044–2.780) 0.033
  6MWT  distancea 0.659 (0.465–0.934) 0.019
 Clinical blood samples
  Urea (mmol/L) 1.197 (0.971–1.475) 0.092
  Log creatinine (mmol/L)a 1.312 (1.048–1.642) 0.018
  Haemoglobin (g/L)a 0.727 (0.570–0.927) 0.010
  Log BNP (ng/L)a 1.471 (1.081–2.000) 0.014
  NTproANP 1.314 (1.029–1.677) 0.028
 Imaging
  E/E′ 1.459 (1.143–1.862) 0.002
  LV mass index 1.296 (1.005–1.671) 0.046
  LAVImax 1.237 (0.992–1.543) 0.059
  LGE MI 1.670 (0.926–3.012) 0.088
  ECV 1.519 (1.076–2.145) 0.018
  iECV 1.516 (1.105–2.079) 0.010
  LAEF 0.726 (0.568–0.927) 0.010
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Kaplan–Meier analysis
Kaplan–Meier survival plots according to LAEF for all patients 
or sinus rhythm alone are shown in Fig. 4. A lower LAEF 
(below median) was associated with increased risk of death 
or HF hospitalization (all Log-Rank p = 0.028; sinus rhythm 
Log-Rank p = 0.036). i.e. the text should match the part labels.
ROC analysis
The AUCs (see Supplementary Fig. 1) of the base model 
and LAEF for predicting outcomes were 0.790 (p < 0.0001) 
and 0.634 (p = 0.008) respectively. The combination of 
the base model and LAEF yielded a higher AUC of 0.806 
(p < 0.0001). The AUC for iECV was 0.611 (p = 0.078).
Discussion
This study prospectively evaluated the prognostic relevance 
of CMR-derived LAEF in a well-phenotyped cohort of 
HFpEF and healthy subjects. The principal findings are that 
(a) LAEF is lower in HFpEF compared to age- and sex-
matched healthy controls (b) LAEF is associated with LA 
volumes and plasma biomarkers of atrial stress/stretch (c) 
inclusive of AF or sinus rhythm alone, lower LAEF is asso-
ciated with adverse outcomes in HFpEF and (d) CMR-LAEF 
is also an independent prognostic marker in HFpEF.
LAEF and HFpEF
Our work adds to a growing body of evidence implicating 
LA remodeling and dysfunction in HF [1]. Impaired LA 
function has previously been noted in conditions associated 
with HFpEF (e.g. diabetes, hypertension) even in the pres-
ence of normal LA size [13]. Furthermore, LAEF is report-
edly lower in HFpEF compared to hypertensive subjects 
with LVH, corroborating our findings [14]. Diminished LA 
contractile reserve as a predictor of exercise incapacity has 
also been shown in subjects with preserved LV ejection frac-
tion with [15] and without heart failure [16].
Current ESC guidelines advocate measurement of LA 
volumes and LV mass in all subjects with suspected HFpEF 
[6]. However, these measures are reliant on image quality 
and adequate endocardial border definition, unfortunately 
lacking in a third of HF cases when assessed with TTE [17]. 
Excellent spatial resolution and contrast, as well as the abil-
ity to scan in any image plane make CMR the current imag-
ing gold standard [17]. Current imaging diagnostic criteria 
provide cut-offs for LAVImax and LV mass that are echo-
cardiography-based and do not routinely incorporate CMR 
[6]. In our study, ROC analyses confirmed the strong signal 
from LAEF in discriminating HFpEF from controls. The 
reasons for this are likely multiple. Firstly, LAEF reduction 
might be a more precise reflection of elevated filling pres-
sures than the other traditional surrogate imaging markers 
of chronic diastolic dysfunction [18]. Similar to our study, 
published literature has demonstrated normal-sized LA in 
approximately one-third of HFpEF subjects [19]. Our find-
ings of reduced LAEF even in the presence of normal-sized 
atria reaffirms prior observations that LA dysfunction likely 
precedes overt LA remodeling in HFpEF [20]. Towards the 
other end of the spectrum, with worsening LA dilatation 
(and likely chronic LV&LA pressure overload), we have 
also demonstrated a close relationship between LA systolic 
function and volumes akin to the Frank-Starling mecha-
nism i.e. LAEF reduces significantly more at higher vol-
umes as contractile reserve becomes exhausted [12, 21]. In 
our subjects, more specific derangements in both reservoir 
Fig. 4  Survival analysis stratified according to median left atrial ejection fraction. Kaplan–Meier analysis stratified according to median left 
atrial ejection fraction for the composite endpoint of death and/or hospitalization with heart failure in a all subjects and b in sinus rhythm only
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(increased LAVmax and reservoir volume) and booster 
pump (increased LAVmin) function were also noted. LA res-
ervoir function may be compromised by reduced LA com-
pliance and LV longitudinal dysfunction typical of HFpEF 
[22]. In addition, LV diastolic dysfunction and concomitant 
elevated filling pressures further contribute to ineffective 
LA active emptying through increasing LA afterload and 
wall tension [23]. Compensatory improvements in conduit 
function may in part explain the lack of difference in conduit 
volume between HFpEF and controls in our study [24].
LAEF as a potential prognostic biomarker
Our prospective study shows CMR-derived LAEF is an 
independent prognostic marker in HFpEF, both with and 
without AF. Previously, TTE-based observational studies 
[25] and HFpEF clinical trials [20, 23] have highlighted 
perturbed LA function as a marker of adverse outcomes. 
Using indices of LA strain measured by speckle tracking, LA 
dysfunction was independently associated with either prior 
[20] or subsequent [23] HF hospitalizations and death [25]. 
In a further retrospective TTE study involving both HFpEF 
and HFrEF, LAEF was independently associated with death 
only in HFpEF [21]. However, in the latter study, the groups 
were not evenly matched and controls comprised subjects 
referred for cardiac catheterization and were perhaps not 
truly representative of a healthy comparator group. In the 
one published CMR study to date evaluating the role of LA 
function in HF (heterogeneous population primarily com-
prising HFrEF), LAEF independently predicted mortality 
and incident AF. However, this retrospective study was again 
limited by referral bias, lacking a control group and exclud-
ing subjects who were in AF (nearly one-third) [12].
The potential value of LAEF as a prognostic biomarker 
may not be confined to HF alone. In a previous study of 312 
subjects free of HF, who were in sinus rhythm and of similar 
age to our cohort, LAEF and LA strain were independent 
predictors of outcomes including future development of AF, 
HF and cardiovascular death [26]. All of the aforementioned 
studies however share intrinsic limitations of TTE [4].
Beyond HF, CMR data also further support LA dysfunc-
tion as a marker of outcomes. Similar to our findings, the 
incremental prognostic value of LA function beyond LAVI-
max has previously been shown in a prospective study of 
asymptomatic subjects from the general population [27] and 
in chronic hypertensive subjects without prevalent cardio-
vascular disease [28]. These findings suggest that LAEF also 
reflects a more advanced state of LA remodeling than LA 
dilation alone [1]. In another population study, LA strain 
using CMR feature tracking was independently associated 
with future development of incident heart failure [29].
LAEF and AF
The association between LA dilation and AF and their 
attendant cardiovascular risk is well recognized [1]. In HF, 
AF risk is also known to increase with diminishing LAEF 
[12]. Interestingly, in our study, AF was not associated with 
adverse outcomes even though event rates were higher in 
this sub-group and LAEF was significantly lower compared 
to those in sinus rhythm. This suggests that LAEF exerts its 
influence on outcomes through alternate mechanisms, either 
directly or indirectly [24, 27]. LA dysfunction as a mediator 
of pulmonary vascular damage, RV dysfunction and pro-
gressive biventricular failure has also been proposed [21]. 
Additional reports have also highlighted that LA dysfunc-
tion in the presence of AF has incremental thromboembolic 
and mortality risk, beyond the CHADS2 (congestive heart 
failure = 1, hypertension = 1, age ≥ 75 = 1, stroke/transient 
ischaemic attack = 2) score. Furthermore, LA dysfunction 
(using echo strain measures) predicts the success of restoring 
and maintaining sinus rhythm following either direct-current 
cardioversion or AF ablation [1].
Potential implications of our study
Our study reaffirms the pathophysiological role of LA dys-
function in HFpEF. CMR-measured biplane LAEF is simple, 
reproducible and provides prognostic information which are 
strengths for consideration as a potential biomarker. CMR is 
becoming increasingly accessible and may more reliably dis-
criminate breathless individuals with equivocal BNP levels 
and suboptimal echocardiographic imaging windows (espe-
cially HFpEF) [6, 17]. Recent data have also suggested that 
LA dysfunction may be a potential therapeutic target [24]. 
While our study suggests that iECV and LA function are not 
related, ongoing clinical trial data may shed further insight 
into whether myocardial fibrosis regression in HFpEF (with 
the anti-fibrotic agent Pirfenidone) may alter LA function as 
a secondary outcome measure [30].
Limitations
This is a single centre study and the results should be con-
firmed in additional HFpEF cohorts. We used a pragmatic 
approach to define our HFpEF population to reflect a real 
world setting as opposed to latest ESC guidelines [6]. The 
presence of diastolic dysfunction was not a pre-requisite 
for study inclusion since recent contemporary clinical trial 
data have highlighted normal diastolic function in approxi-
mately a third of such patients [31]. Our data does however 
also provide compelling evidence (natriuretic peptides) that 
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our patient cohort truly had HF and the event rates (48%) 
are similar to that of previous outcome studies in HFpEF. 
Our control group included hypertensive subjects and was 
therefore not totally free of cardiovascular disease. However, 
LAEF was also lower in HFpEF compared to both hyperten-
sive and non-hypertensive controls.
Conclusions
CMR-derived LAEF is lower in HFpEF compared to 
age- and sex-matched controls and independently predicts 
outcomes.
Acknowledgements The authors would like to thank the CMR radiog-
raphers at Glenfield Hospital for image acquisition and Bristol Myers 
Squibb for facilitating plasma biomarker (NTpro-ANP) analysis.
Author contributions PK recruited the patients, supervised the study 
visits and CMR scans (with AS and JNK), analyzed the data, performed 
the statistical analysis and drafted the initial manuscript along with 
JRA. ASHC, PK and GPM undertook qualitative LGE image analy-
sis. GGS undertook follow-up outcome data collection. JRA and PK 
performed inter-observer assessments. BNP and other serum sampling 
were undertaken in the hospital pathology laboratory under the super-
vision of PG. Plasma NTpro-ANP samples were analyzed by JY and 
LZ. PK, IBS, LLN and GPM conceived the study. All authors critically 
revised the manuscript for important intellectual content, approved the 
final version for submission and agree to be accountable for all aspects 
of the work in ensuring that questions relating to the accuracy or integ-
rity of any part of the work are appropriately investigated and resolved.
Funding This work was supported by the National Institute for Health 
Research (NIHR) Leicester Cardiovascular Biomedical Research Cen-
tre overall Project Grant: IRS_BRU_0211_20033 and the John and 
Lucille Van Geest Foundation. Professor GPM was supported by NIHR 
Research Fellowships (PDF-2011–0451 and CDF 2014–07-045).
Compliance with ethical standards 
Conflict of interest Lei Zhao and Jing Yang are employees of Bristol 
Myers Squibb which facilitated plasma NTpro-ANP analysis. All other 
authors declare that they have no competing interests relevant to this 
study. All authors also state that they have full control of all primary 
data and that they agree to allow the journal to review their data if 
requested.
Ethical approval The study was approved by the United Kingdom 
National Research Ethics Service Committee East Midlands – Not-
tingham (reference: 12/EM/0222). Informed consent was obtained 
from all individual participants included in the study. The study was 
performed in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Hoit BD (2014) Left atrial size and function: role in prognosis. 
J Am Coll Cardiol 63(6):493–505. https ://doi.org/10.1016/j.
jacc.2013.10.055
 2. Fang F, Lee AP, Yu CM (2014) Left atrial function in heart failure 
with impaired and preserved ejection fraction. Curr Opin Cardiol 
29(5):430–436. https ://doi.org/10.1097/HCO.00000 00000 00009 1
 3. Hudsmith LE, Petersen SE, Francis JM et al (2005) Normal human 
left and right ventricular and left atrial dimensions using steady state 
free precession magnetic resonance imaging. J Cardiovasc Magn R 
7(5):775–782. https ://doi.org/10.1080/10976 64050 02955 16
 4. Kuhl JT, Lonborg J, Fuchs A et al (2012) Assessment of left atrial 
volume and function: a comparative study between echocardi-
ography, magnetic resonance imaging and multi slice computed 
tomography. Int J Cardiovasc Imaging 28(5):1061–1071. https ://
doi.org/10.1007/s1055 4-011-9930-2
 5. Agner BF, Kuhl JT, Linde JJ et al (2014) Assessment of left atrial 
volume and function in patients with permanent atrial fibrillation: 
comparison of cardiac magnetic resonance imaging, 320-slice 
multi-detector computed tomography, and transthoracic echocar-
diography. Eur Heart J Cardiovasc Imaging 15(5):532–540. https 
://doi.org/10.1093/ehjci /jet23 9
 6. Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guide-
lines for the diagnosis and treatment of acute and chronic heart 
failure: the task force for the diagnosis and treatment of acute 
and chronic heart failure of the European Society of Cardiology 
(ESC) developed with the special contribution of the Heart Failure 
Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. 
https ://doi.org/10.1093/eurhe artj/ehw12 8
 7. Kanagala P, Cheng ASH, Singh A et al (2018) Diagnostic and 
prognostic utility of cardiovascular magnetic resonance imag-
ing in heart failure with preserved ejection fraction: implications 
for clinical trials. J Cardiovasc Magn Reson 20(1):4. https ://doi.
org/10.1186/s1296 8-017-0424-9
 8. Palau P, Dominguez E, Nunez E et al (2016) Six-minute walk 
test in moderate to severe heart failure with preserved ejection 
fraction: useful for functional capacity assessment? Int J Cardiol 
203:800–802. https ://doi.org/10.1016/j.ijcar d.2015.11.074
 9. Tang H, Panemangalore R, Yarde M et al (2016) 384-Well mul-
tiplexed luminex cytokine assays for lead optimization. J Biomol 
Screen 21(6):548–555. https ://doi.org/10.1177/10870 57116 64416 4
 10. Kanagala P, Cheng ASH, Singh A et al. (2019) Relationship 
between focal and diffuse fibrosis assessed by CMR and clinical 
outcomes in heart failure with preserved ejection fraction. JACC 
Cardiovasc Imaging. https ://doi.org/10.1016/j.jcmg.2018.11.031
 11. Gulati A, Ismail TF, Jabbour A et al (2013) Clinical utility and 
prognostic value of left atrial volume assessment by cardiovascular 
magnetic resonance in non-ischaemic dilated cardiomyopathy. Eur 
J Heart Fail 15(6):660–670. https ://doi.org/10.1093/eurjh f/hft01 9
 12. Pellicori P, Zhang J, Lukaschuk E et al (2015) Left atrial function 
measured by cardiac magnetic resonance imaging in patients with 
heart failure: clinical associations and prognostic value. Eur Heart 
J 36(12):733–742. https ://doi.org/10.1093/eurhe artj/ehu40 5
 13. Mondillo S, Cameli M, Caputo ML et al (2011) Early detection 
of left atrial strain abnormalities by speckle-tracking in hyper-
tensive and diabetic patients with normal left atrial size. J Am 
Soc Echocardiogr 24(8):898–908. https ://doi.org/10.1016/j.
echo.2011.04.014
 14. Melenovsky V, Borlaug BA, Rosen B et al (2007) Cardiovascular 
features of heart failure with preserved ejection fraction versus 
nonfailing hypertensive left ventricular hypertrophy in the urban 
Baltimore community: the role of atrial remodeling/dysfunction. 
J Am Coll Cardiol 49(2):198–207. https ://doi.org/10.1016/j.
jacc.2006.08.050
 The International Journal of Cardiovascular Imaging
1 3
 15. Kusunose K, Motoki H, Popovic ZB et al (2012) Independent 
association of left atrial function with exercise capacity in patients 
with preserved ejection fraction. Heart 98(17):1311–1317. https 
://doi.org/10.1136/heart jnl-2012-30200 7
 16. Tan YT, Wenzelburger F, Lee E et al (2010) Reduced left atrial 
function on exercise in patients with heart failure and normal ejec-
tion fraction. Heart 96(13):1017–1023. https ://doi.org/10.1136/
hrt.2009.18911 8
 17. Bellenger NG, Burgess MI, Ray SG et al (2000) Comparison of 
left ventricular ejection fraction and volumes in heart failure by 
echocardiography, radionuclide ventriculography and cardiovas-
cular magnetic resonance; are they interchangeable? Eur Heart J 
21(16):1387–1396. https ://doi.org/10.1053/euhj.2000.2011
 18. Cameli M, Lisi M, Mondillo S et al (2010) Left atrial longitudinal 
strain by speckle tracking echocardiography correlates well with 
left ventricular filling pressures in patients with heart failure. Car-
diovasc Ultrasound 8:14. https ://doi.org/10.1186/1476-7120-8-14
 19. Zile MR, Gottdiener JS, Hetzel SJ et al (2011) Prevalence and 
significance of alterations in cardiac structure and function in 
patients with heart failure and a preserved ejection fraction. Circu-
lation 124(23):2491–2501. https ://doi.org/10.1161/CIRCU LATIO 
NAHA.110.01103 1
 20. Santos AB, Kraigher-Krainer E, Gupta DK et al (2014) Impaired 
left atrial function in heart failure with preserved ejection frac-
tion. Eur J Heart Fail 16(10):1096–1103. https ://doi.org/10.1002/
ejhf.147
 21. Melenovsky V, Hwang SJ, Redfield MM et al (2015) Left atrial 
remodeling and function in advanced heart failure with preserved 
or reduced ejection fraction. Circ Heart Fail 8(2):295–303. https 
://doi.org/10.1161/CIRCH EARTF AILUR E.114.00166 7
 22. Barbier P, Solomon SB, Schiller NB et al (1999) Left atrial relaxa-
tion and left ventricular systolic function determine left atrial res-
ervoir function. Circulation 100(4):427–436
 23. Santos AB, Roca GQ, Claggett B et al. (2016) Prognostic rel-
evance of left atrial dysfunction in heart failure with preserved 
ejection fraction. Circ Heart Fail. https ://doi.org/10.1161/CIRCH 
EARTF AILUR E.115.00276 3
 24. Casaclang-Verzosa G, Gersh BJ, Tsang TS (2008) Structural and 
functional remodeling of the left atrium: clinical and therapeutic 
implications for atrial fibrillation. J Am Coll Cardiol 51(1):1–11. 
https ://doi.org/10.1016/j.jacc.2007.09.026
 25. Freed BH, Daruwalla V, Cheng JY et al. (2016) Prognostic util-
ity and clinical significance of cardiac mechanics in heart failure 
with preserved ejection fraction: importance of left atrial strain. 
Circ Cardiovasc Imaging. https ://doi.org/10.1161/CIRCI MAGIN 
G.115.00375 4
 26. Cameli M, Lisi M, Focardi M et al (2012) Left atrial deformation 
analysis by speckle tracking echocardiography for prediction of 
cardiovascular outcomes. Am J Cardiol 110(2):264–269. https ://
doi.org/10.1016/j.amjca rd.2012.03.022
 27. Gupta S, Matulevicius SA, Ayers CR et al (2013) Left atrial struc-
ture and function and clinical outcomes in the general popula-
tion. Eur Heart J 34(4):278–285. https ://doi.org/10.1093/eurhe artj/
ehs18 8
 28. Kaminski M, Steel K, Jerosch-Herold M et al (2011) Strong car-
diovascular prognostic implication of quantitative left atrial con-
tractile function assessed by cardiac magnetic resonance imaging 
in patients with chronic hypertension. J Cardiovasc Magn Reson 
13:42. https ://doi.org/10.1186/1532-429X-13-42
 29. Habibi M, Chahal H, Opdahl A et al (2014) Association of CMR-
measured LA function with heart failure development: results 
from the mesa study. JACC Cardiovasc Imaging 7(6):570–579. 
https ://doi.org/10.1016/j.jcmg.2014.01.016
 30. Lewis GA, Schelbert EB, Naish JH et al. (2019) Pirfenidone in 
heart failure with preserved ejection fraction-rationale and design 
of the PIROUETTE trial. Cardiovasc Drugs Ther. doi:10.1007/
s10557–019–06876-y
 31. Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone 
for heart failure with preserved ejection fraction. N Eng J Med 
370(15):1383–1392. https ://doi.org/10.1056/NEJMo a1313 731
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Prathap Kanagala1,2  · Jayanth R. Arnold1 · Adrian S. H. Cheng3 · Anvesha Singh1 · Jamal N. Khan1 · 
Gaurav S. Gulsin1 · Jing Yang4 · Lei Zhao4 · Pankaj Gupta1 · Iain B. Squire1 · Leong L. Ng1 · Gerry P. McCann1
 Jayanth R. Arnold 
 jra14@leicester.ac.uk
 Adrian S. H. Cheng 
 adrianshcheng@gmail.com
 Anvesha Singh 
 as707@leicester.ac.uk
 Jamal N. Khan 
 mally777@hotmail.com
 Gaurav S. Gulsin 
 gg149@leicester.ac.uk
 Jing Yang 
 jing.yang1@bms.com
 Lei Zhao 
 lei.zhao2@bms.com
 Pankaj Gupta 
 pankaj_gupta54@hotmail.com
 Iain B. Squire 
 is11@leicester.ac.uk
 Leong L. Ng 
 lln1@leicester.ac.uk
 Gerry P. McCann 
 gpm12@leicester.ac.uk
1 Department of Cardiovascular Sciences, University 
of Leicester, National Institute for Health Research (NIHR) 
Leicester Biomedical Research Centre, Leicester, UK
2 Aintree University Hospital, Liverpool, UK
3 Kettering General Hospital NHS Foundation Trust, 
Kettering, UK
4 Bristol-Myers Squibb, Princeton, NJ, USA
